169 related articles for article (PubMed ID: 30549085)
21. Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies.
Chen V; Shao W
Health Care Sci; 2023 Dec; 2(6):381-391. PubMed ID: 38938625
[TBL] [Abstract][Full Text] [Related]
22. Health economics of medical devices: opportunities and challenges.
Simoens S
J Med Econ; 2008; 11(4):713-7. PubMed ID: 19450077
[TBL] [Abstract][Full Text] [Related]
23. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
Shiroiwa T; Fukuda T; Ikeda S; Takura T
Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
[TBL] [Abstract][Full Text] [Related]
24. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
Martelli N; van den Brink H
Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
[TBL] [Abstract][Full Text] [Related]
25. Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs.
Takayama A; Narukawa M
Ther Innov Regul Sci; 2016 May; 50(3):361-367. PubMed ID: 30227073
[TBL] [Abstract][Full Text] [Related]
26. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Thatte U; Hussain S; de Rosas-Valera M; Malik MA
Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
[TBL] [Abstract][Full Text] [Related]
27. Comparison of prescription reimbursement methodologies in Japan and the United States.
Akaho E; MacLaughlin EJ; Takeuchi Y
J Am Pharm Assoc (2003); 2003; 43(4):519-26. PubMed ID: 12952317
[TBL] [Abstract][Full Text] [Related]
28. The impact of HTA and procurement practices on the selection and prices of medical devices.
Callea G; Armeni P; Marsilio M; Jommi C; Tarricone R
Soc Sci Med; 2017 Feb; 174():89-95. PubMed ID: 28013109
[TBL] [Abstract][Full Text] [Related]
29. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
[TBL] [Abstract][Full Text] [Related]
30. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Assessment of Premium Rates for Clinical Usefulness in New Drug Price Calculation in Japan.
Takayama A; Kobayashi E; Nakamura T; Narukawa M
Ther Innov Regul Sci; 2017 Sep; 51(5):582-588. PubMed ID: 30231680
[TBL] [Abstract][Full Text] [Related]
32. Examining the Impact of the Current Reimbursement Regulation on Patient Access to Innovative Medical Devices in Taiwan: Insights From 8 Years' Reimbursement Data.
Peng JY; Lee SS; Lin CR; Lee H; Chen YC
Value Health Reg Issues; 2024 Jul; 42():100978. PubMed ID: 38350187
[TBL] [Abstract][Full Text] [Related]
33. Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.
Lee JH
Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33800373
[TBL] [Abstract][Full Text] [Related]
34. Scientific evaluation and pricing of medical devices and associated procedures in France.
Gilard M; Debroucker F; Dubray C; ; Allioux Y; Aper E; Barat-Leonhardt V; Brami M; Carbonneil C; Chartier-Kastler E; Coqueblin C; Fare S; Giri I; Goehrs JM; Levesque K; Maugendre P; Parquin F; Sales JP; Szwarcensztein K
Therapie; 2013; 68(4):193-208. PubMed ID: 23981256
[TBL] [Abstract][Full Text] [Related]
35. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
36. Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
[TBL] [Abstract][Full Text] [Related]
37. Impact of change in the price of percutaneous coronary intervention devices on medical expenses.
Kuroda N; Kobayashi Y; Desai K; Costantini C; Kobayashi M; Komuro I
Circ J; 2003 Jul; 67(7):576-8. PubMed ID: 12845178
[TBL] [Abstract][Full Text] [Related]
38. Drug Policy in Latvia.
Silins J; Szkultecka-Dębek M
Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
[TBL] [Abstract][Full Text] [Related]
39. Which barriers prevent the efficient use of resources in medical device sectors?
Simoens S
Appl Health Econ Health Policy; 2009; 7(4):209-17. PubMed ID: 19905034
[TBL] [Abstract][Full Text] [Related]
40. Reimbursement Coverage and Pricing Systems for Single-Use Devices in Asia-Pacific: Japan, Taiwan, Korea, and Australia Compared.
Lee SS; Symonds D; Kamogawa S; Sato M; Chiang E; Salole E
Value Health Reg Issues; 2015 May; 6():126-129. PubMed ID: 29698183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
